InVivoMab anti-human PD-1 (CD279) BE0193-R001mg from Bio X Cell | Biocompare.com

Supplier Images

InVivoMab anti-human PD-1 (CD279)

Be the first to write a review!

Citations:

Supplier Page from
Bio X Cell for
InVivoMab anti-human PD-1 (CD279)

The InVivoMab anti-human PD-1 (CD279) Antibody from Bio X Cell is a Mouse Monoclonal antibody to PDCD1. This antibody recognizes Homo Sapiens, and Human antigen. The InVivoMab anti-human PD-1 (CD279) Antibody has been validated for the following applications: In Vivo, Block/Neutralize/Inhibit, and Flow Cytometry.

Description

Bio X Cell InVivoMAb anti-human PD-1 (CD279) Monoclonal Antibody has the following reported applications: in vivo PD-1 blockade in humanized mice, Flow cytometry. It features greater than 95% purity, ultra-low endotoxin levels, and are preservative, stabilizer, and carrier protein-free

Product Specs
ItemInVivoMab anti-human PD-1 (CD279)
CompanyBio X Cell
Price Pricing Info Supplier Page View Company Product Page
Catalog NumberBE0193-R001mg
Quantity1 mg
Applicationsin vivo PD-1 blockade in humanized mice, Flow cytometry
ConcentrationLot specific,typically between 4-11 mg/ml
Conjugate/TagUnconjugated
ReactivityHuman
TargetPD-1
IsotypeIgG1, κ
CloneJ110
Hostmouse
NCBI Full Gene Nameprogrammed cell death 1
NCBI Gene AliasesCD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1
ClonalityMonoclonal
Antibody TypePrimary Antibody
Purity>95%, Determined by SDS-PAGE
FormatPBS, pH 7.0, Contains no stabilizers or preservatives
Research AreaCancer Biology, Immune Checkpoint Protein, Immunology

Specifications/Features

Other available quantities: Available in 1, 5, 10, 25, 50, 100 mg and bulk sizes. Academic discount available.

Endotoxin: <2EU/mg (<0.002EU/µg), Determined by LAL gel clotting assay

Add to Compare List

Bio X Cell

Bio X Cell

39 Labombard Rd

Lebanon, NH 03766

United States

Phone: 1-866-787-3444

Email: customerservice@bxcell.com

Company Profile

Website: bioxcell.com

(1) BRAF and MEK Inhibitors Increase PD-1-Positive Melanoma Cells Leading to a Potential Lymphocyte-Independent Synergism with Anti-PD-1 AntibodyClinical cancer research : an official journal of the American Association for Cancer ResearchJuly 15, 2018Sanlorenzo M, Vujic I, Floris A, Novelli M, Gammaitoni L, Giraudo L, Macagno M, Leuci V, Rotolo R, Donini C, et al.

(2) Programmed cell death protein 1 and programmed death-ligand 1 are expressed on the surface of some small-cell lung cancer linesAmerican journal of cancer researchJanuary 1, 2015Yamane H, Isozaki H, Takeyama M, Ochi N, Kudo K, Honda Y, Yamagishi T, Kubo T, Kiura K, Takigawa N.

(3) Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation: attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responsesJournal of immunology (Baltimore, Md. : 1950)January 15, 2003Bennett F, Luxenberg D, Ling V, Wang IM, Marquette K, Lowe D, Khan N, Veldman G, Jacobs KA, Valge-Archer VE, et al.

Be the First to Write a Review!